Idera Pharmaceuticals bucked the biotech sell-off last month by gaining more than 20%. The company, which currently doesn't have any products on the market, is working on an intriguing new cancer therapy for patients with specific genetic mutations and in the fourth quarter, Idera Pharmaceuticals plans to release data showing whether or not IMO 8400 is effective at treating a rare form of cancer known as Waldenstrom'smacroglobulinemia.
View the slideshow to learn more about Idera Pharmaceuticals and what's driving interest in its shares higher.
Continue Reading Below
The article Why Idera Pharmaceuticals Soared 20% in September originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.